Development of Variable Volume Automated Mandatory Boluses for Patient-controlled Epidural Analgesia During Labour
Launched by KK WOMEN'S AND CHILDREN'S HOSPITAL · Jul 4, 2019
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to provide pain relief during labor for women who are having their first baby. The researchers are testing a method called Variable Volume Automated Mandatory Boluses (VVAMB), which aims to give a larger amount of pain medication quickly. This could help spread the medicine better and reduce the chance of unwanted side effects that can occur with traditional methods, making labor a smoother experience.
To participate in this trial, women must be healthy, at least 36 weeks pregnant, and in early labor with a single baby. They also need to be able to receive a specific type of epidural pain relief. However, women with certain medical conditions or complications, such as specific types of high blood pressure or certain fetal positions, will not be eligible. If someone joins the study, they can expect to receive personalized pain relief during labor and contribute to important research that could improve care for future parents.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Healthy (American Society of Anesthesiologists (ASA) physical status 1 and 2) primiparous parturient at term (≥36 weeks gestation);
- • Singleton fetus;
- • In early labor stage (cervical dilation ≤5cm);
- • Request labor epidural analgesia and able to administer combined spinal epidural analgesia (CSEA) according to protocol.
- Exclusion Criteria:
- • Non-cephalic fetal presentation;
- • Obstetric (e.g. pre-eclampsia, premature rupture of amniotic membranes for more than 48 hours, gestational diabetes on insulin, pregnancy-induced hypertension on medication) and uncontrolled medical (e.g. cardiac disease) complications;
- • Have contraindications to neuraxial blockade or have received parenteral opioids within last 2 hours;
- • Dural puncture/ suspected dural puncture at initiation of CSEA.
About Kk Women's And Children's Hospital
KK Women’s and Children’s Hospital is a leading healthcare institution dedicated to providing comprehensive medical services for women and children. As a prominent clinical trial sponsor, the hospital is committed to advancing medical research and improving patient outcomes through innovative studies. With a focus on maternal and child health, KK Women’s and Children’s Hospital collaborates with multidisciplinary teams of experts to conduct rigorous clinical trials that adhere to the highest ethical standards. Their mission is to enhance the quality of care through evidence-based practices, fostering a healthier future for families in the community and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Singapore, , Singapore
Patients applied
Trial Officials
Wan Ling Leong, FANZCA
Principal Investigator
KK Women's and Children's Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials